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New drugs and technologies for cancer treatment are being developed at a rate that has
created a reimbursement crisis. This article discusses third-party concerns about this problem
and describes generic criteria that have proven to be useful in assessing any new technology. It
is equallyimportant to discontinue funding ofineffective andobsolete therapies as it isto devise
a strategy for identifying and encouraging the development of new therapy that will be both
clinicallyuseful and cost-effective. Examples are provided toshowthat these are not necessarily
mutuallyexclusive goals. Off-label application ofstandard therapy aswell as the fundingofnew
cancer therapy are considered. High-dose chemotherapy with autologous stem-cell support for
treatment of a variety of neoplasms has become a major reimbursement challenge. Other
technologies such as autolymphocyte therapy and use ofcolony-stimulating factors are consid-
ered in detail. Finally, a process for deciding how to fund new cancer therapy is described.
The discussion in this paper is confined to reimbursement issues ofcancer therapy
ingeneral, and as related to newtherapeutictechnologies. Inevitably, theseconcerns
are linked to the broader problems associated with rising health care costs. Some of
these critical issues are beyond the scope of our topic, but should be identified. For
example, the enormous potential costs to third-party payers from litigation gener-
ated by denial of benefits for investigational therapy, as well as the influence of
politics, and the power of lobbying groups on corporate coverage decisions deserve
thoughtful, constructive solutions. Similarly, the effect of 35 million Americans
without health insurance, ofunemployment, poverty, and the irrational distribution
ofaccess to medical care on the national health budget are key issues that cannot be
covered in a discussion of this sort. There is, however, a relentless force propelling
medical costs upward that is clearly related to cancer treatment.
The rapid emergence ofnew technologies in health care in recentyears has placed
an enormous financial burden upon third-party payers. According to data from A.
Foster Higgins, a benefits consulting firm, spending on company-paid health care
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averaged in excess of$2,300 per employee by 1988, up 19 percent over 1987 levels. A
current review by Tom Wicker [1] cites a rise in corporate medicalbenefits to $3,161
per employee in 1990, 44 percent more than in 1988. Even this figure is misleading,
since the major cause of rising health care costs is the expense ofcaring for a small
number of people (the expensive top 10 percent) with extremely severe medical
problems. Annual costs for patients in this group soared to $10,529. In a study by
Ohio's Blue Cross-Blue Shield, "50 people-victims of major, sometimes chronic
problems like muscular dystrophy, cancer and mental disorders-alone required
more in health carebenefits than 40,000 ofthe people in the 90 percentrequiringthe
least care" [1].
Although Wicker suggests that strategies such as "individual case management"
and establishment of "centers of excellence" to negotiate fixed fees for expensive
procedures may drive down current high costs of the kind of treatment needed by
only a small number ofpatients, these programs, in fact, have been established and
operative by private insurers for more than five years without significantly reducing
the rise in medical costs.
One reason for the growth in expenditure is the increasing sophistication of
medical science, a significant portion ofwhich is investigational therapy. John Burry,
Jr., chief executive of Ohio's Blue Cross-Blue Shield, asked recently, "Is it fair to
allocate the astronomical costs of these quasi-experimental (in some cases) proce-
dures and technology to the employer and/or the individual?" [1].
One view, held by those who have not assessed this problem critically, is that
third-party payers should continue to fund these ever-rising costs. The AIDS
epidemic has been largely responsible for bringing this problem to the forefront, as
concerned individuals seekways to assure that the afflicted have access to promising
therapy at a time when spiraling cost has become an issue that can no longer be
ignored [2].
The funding ofinvestigational therapy is a societal problem that involves not only
laboratory and clinical researchers, but also governmental agencies (National Can-
cer Institute, HCFA, Medicare, Medicaid), our elected representatives in the House
and Senate, the Office ofthe Secretary ofHealth and Human Services, the pharma-
ceutical industry, the legal profession, corporations andbusinesseswho are expected
to pay all or a substantial part ofthe health care costs oftheir employees, as well as
third-party payers. While reimbursement of investigational cancer care is the focus
ofthis paper, costswill be incurred forthe care ofcancerpatientswhethertreatment
is considered standard or investigational. Since all parties involved are dismayed by
rising health care costs, no one group can abdicate responsibility.
Dr. George P. Canellos posed the fundamental question succinctly. "A standoff
has resulted, leading many to question: Who should payfor translation oflaboratory
science to the bedside?" [3].
Technology assessment by third-party payers focuses on three distinct areas: new
technology, future technology, andfirmly established technology.
New
The primary purpose of the assessment procedure is to determine whether the
new technology is broadly accepted as medically necessary or is investigational or
experimental. The process generally begins with a comprehensive review ofmedical
literature describing tentative conclusions reached by scientific studies. Additional
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information or evaluations can be solicited from federal agencies, medical specialty
societies, other insurers, and manufacturers, as well as renowned professionals in
their respective fields. The following set ofcriteria are useful to aid in the evaluation
ofnew technology.
Is there an appropriate rationale for the treatment?
Is there evidence that the treatment is effective?
Is there evidence that the treatment is harmful?
Do the benefitsjustify the immediate and delayed risks ofthe treatment?
Has the treatment been endorsed by the appropriate medical authorities, such
as the Food and Drug Administration (FDA), the American Medical Association
(AMA), or other medical specialty societies or specialists? Is the treatment being
covered by Medicare orother public programs?
Is the device or treatment the subject ofongoing investigation or research?
Is the treatment only in use in aforeign country orbyone provider?
Is the treatment legal in this country?
Have controlled clinicaltrialsbeencarried out that demonstrate the treatment's
efficacy?
Ifthere have been no controlled clinical trials, is the disease so rare as to render
the requirement ofcontrolled studies inappropriate? Ifso, is the treatment safe?
Are there appropriate indicators that maybe used toidentifythosepatientswho
are likely to respond and those who will not? If so, under what conditions is this
treatment appropriate?
Is this treatment or technology the only one available to achieve the desired
outcome, or are there other related treatments or technologies that provide an
identical outcome in a more cost-effective manner?
Future
Future technology should be handled in very much the same manner as new with
respect to reviewing the medical literature. It is often premature, however, to apply
the "broadly accepted" test because not enough scientific studies have been com-
pleted. In such instances, the initial findings should be documented and the topic
placed on a tracking list forfuture review and to follow its development.
FirmlyEstablished
On occasion, previously reviewed technology, which has been broadly accepted as
medically necessary, is subsequently challenged as to its effectiveness, based upon
new evidence. In such instances, the process of intensive literature review is
undertaken, and positions taken by pertinent agencies and/or societies relevant to
the questionable technology are solicited. If the therapy is now determined to be
obsolete, it should no longer be considered appropriate for coverage by third-party
payers.
In applying these evaluation criteria to specific cancer treatments, a reasonable
"gold standard" for any drug for insurance coverage would seem to be FDA
approval. Although this status appears to be a criterion that logically cannot be
challenged, the author recently had an experience regarding a drug (interleukin 2)
that had been denied FDA approval on the basis of insufficient clinical data. The
drug had nevertheless been administered to an insured with cancer, and coverage
was denied. This denial of benefits was challenged by the insured, who appealed
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through the offices of the Texas State Legislature. A senator, who had no medical
expertise, dismissed out ofhand lack ofFDA approval as avalid reason for denial of
benefits! It is unlikely that this view would find widespread support in the scientific
community. Another related issue in the case: what would be the liability of the
third-party payer for damages if the insured were harmed by a non-FDA-approved
drug thatwas reimbursed by the insurer?
The process necessary to obtain FDA approval for a new drug is tedious and
expensive, usually requiring several years at a cost ofmillions ofdollars. To facilitate
access to new drugs, currently class C classification ofa drugby the National Cancer
Institute or treatment investigational new drug (IND) status by the FDA, identifies
promising treatments that are put on an accelerated pace ofinvestigation at certain
identified institutions. Reimbursement for such special categories by third-party
payers (Medicare, Medicaid, private insurance) is an issue requiring serious consid-
eration. In this context, payers should identify centers ofexcellence which would be
appropriate sites for covered use of drugs in these special categories. Reimburse-
ment for the use of other investigational drugs, as recommended by the Lasagna
Committee [2], should be considered if such use has been approved by expert
government agencies, in authoritative medical compendia, or by a committee estab-
lished by the Secretary ofHealth and Human Services. The Lasagna Committee also
suggested: (1) use of the treatment IND earlier in the drug development process
where alternative therapies are unavailable, and (2) expanded access (parallel track)
IND to investigational drugswhen there is assurance that adequate clinical trials are
in progress andwill not be compromised.
Off-label use of FDA-approved drugs is commonly practiced by medical oncolo-
gists. If such off-label use proves to be effective, prompt publication ofresults in the
peer-reviewed literature will facilitate third-party reimbursement. As a practical
matter, a major insurance carrier, processing millions of claims every week, cannot
identify off-label use of approved drugs unless the dollar amount becomes high
profile. In addition, it is not cost-effective for the pharmaceutical industry to expend
the dollars and effort to gain FDA approval for indications not included in the initial
labeling ifsuch use is alreadywidespread and reimbursed.
The most widely publicized "standoff" between payers and clinical investigators
has been over the use ofhigh-dose chemotherapy (HDChx) followed by autologous
bone marrow transplantation (ABMT) for a number of disseminated cancers,
particularly carcinoma ofthe breast.
When I first assessed this technology in 1988, it was clear that it was an emerging
new technology that appeared still to be investigational and not reimbursable under
the contract language, which defined covered treatment as "broadly accepted as
medically necessary." Several experts in the fields ofmedical and radiation oncology
who were contacted by the author at that time (1988) regarding HDChx and ABMT
for breast cancer emphatically agreed that this was still an investigational treatment.
In 1988, I conducted a comprehensive technology assessment of HDChx and
ABMT, considering notjust breast cancer but its use for all neoplasms. Not only did
this strategyhave ahigh dollar cost($40,000 to$70,000pertransplant) but italsowas
associated with a number ofscientificquestions that remained tobe answered. Ifthe
patient's marrow already contained tumor cells, did it need to be "purged" ofthese
cells before reinfusing, and, ifso, what was the optimum technology for purging? At
that time, there was a substantial risk associated with ABMT: 10 percent mortality,
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10 percent failure to recover normal blood counts within two months of the
treatment, and severe, major life-threatening toxicity in up to 15 percent ofpatients.
Itwas not clearwho shouldbe treatedwith the regimen. The available information in
1988 suggested that this regimen salvaged some patients, but the data were not
mature [4-10].
There was, at that time, an appropriate rationale for this technology and early
evidence that it was effective in a fraction of the patients treated. There was,
however, no generic official endorsement of treatment, and no controlled clinical
trialswere available. Thepotentialtoxicitywas apparent, and itwasnotclearthat the
treatment outcome outweighed the risks.
Over the course ofthe next year, although there were no controlled clinical trials,
new published studies demonstrated successful and long-term survival in some
patientswith relapsedHodgkin'sdisease, non-Hodgkin'slymphoma, stage III and IV
neuroblastoma, and second-remission acute leukemia. Mortality and morbidity
associatedwith HDChx remained substantial, but, with no other therapeuticoptions
available, the potential benefit appeared to justify the risk. The issue of marrow
purging remained unresolved, but disease-free survival following infusion of un-
purged marrow in these four diseases suggested that purging might not be a critical
issue. Therefore, early in 1989 I recommended coverage for HDChxwith ABMT for
the four neoplasms specified above. Independently, the National Center for Health
Services and Health Care Technology Assessments published a position paper that
officially endorsed HDChxwith ABMT for the above diseases, but at the same time
indicated that the data did not support the use ofthis technology for other tumors.
During 1990 and early 1991, an increasing number of requests were made by
providers for reimbursement for HDChx and ABMT for patients with breast cancer
in a variety of stages and situations. The author searched the literature extensively,
but other than individual, and usually small, series from a variety of institutions,
there were no published controlled clinical trials toverify the efficacy ofthis strategy
in the treatment ofbreast cancer and no parameters to identify patients who would
be suitable candidates for HDChx and ABMT [11-27]. Reimbursement was denied,
relations with providers became acrimonious, and litigation was increasing as time
went on. Not surprisingly, when individual cases came to court, a favorablejudgment
for third-party payers was impossible to obtain, in spite oflack ofcontrolled clinical
trials. How could a medically unsophisticated judge deny treatment to a patient
eventually doomed to die of breast cancer, particularly if the afflicted insured
appeared in his courtroom? Likewise it became equally impossible to obtain a
favorable judgment (for third-party payers) to deny coverage of treatment that had
been given with the mutual consent of payers and insured (with the monies held in
escrow, pending outcome of litigation) on the understanding that such litigation
would take place post facto so the patient could proceed with treatment without
delay and the legal questions debated in a less emotionally charged environment.
Once again Dr. Canellos's "standoff" was apparent.
A number of actions were subsequently undertaken by clinical investigators and
some third-party payers. Controlled clinical trials are under way in both a multi-
institutional joint study sponsored by the Philadelphia Bone Marrow Transplant
Group (Protocol PBT-2) as well in South Western Oncology Group (SWOG) and
Eastern Cooperative Oncology Group (ECOG) trials. Also, Blue Cross-Blue Shield
agreed to reimburse this treatment for breast cancer patients entering controlled
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trials: that approval, however, applied to some but not all Blue Cross-Blue Shield
plans. This approach raised two interesting questions. First, why should a payer
reimburse for specific cancer therapy for some ofits insureds, while denying coverage
for insureds enrolled in other Blue Cross-Blue Shield plans not included in the study
groups? Second, how to answer serious questions raised by those patients entering
clinical trials? Some would be required to enter a control arm that denied access to a
now well-publicized treatment for breast cancer.
More recently [28], the DATTA (Diagnostic and Therapeutic Technology Assess-
ment) group at the AMA re-reviewed ABMT and generally agreed that as an adjunct
to HDChx it appeared to be no longer investigational, with the exception of marrow
purging techniques. Their report, however, did not include a consideration of the
efficacy ofHDChx in breast cancer.
In 1991, as a result of troubling reimbursement issues surrounding the treatment
ofbreast cancer with HDChx and ABMT, even though controlled clinical trials were
as yet not completed and reported, several third-party payers opted for coverage of
patients after individual review by a medical director.
Having done this, it remained to develop criteria to identify breast cancer patients
suitable for HDChx and ABMT: criteria that would be acceptable to the clinical
community as well as to nationally recognized peer-review organizations. After a
review of the literature and critique by a DATTA panelist at AMA, I identified
criteria (Table 1) [29-37], and evidence tables were constructed (Table 2) [38-44].
At this time, we recognized both ABMT and peripheral stem-cell transplantation
(PSCT) as equally acceptable and effective technologies, particularly since PSCT
would allow breast cancer patients with insufficient or contaminated marrow to be
treated with HDChx.
In the evidence tables for patients with stageII and stage III breast cancer at high
risk ofrelapse (ten or more involved axillary nodes), relapse-free survival data show a
clear advantage for HDChx and ABMT at three and five years. In patients with stage
IV breast cancer, comparing repetitive conventional-dose chemotherapy with single
high-dose treatment and ABMT after standard induction chemotherapy, complete
remission rates are 10 percent and 58 percent, respectively, and median response and
survival durations impressively lengthened in the group receiving standard induction
chemotherapy followed by HDChx and ABMT.
In addition to breast cancer, third-party payers will need to conduct ongoing
research pertaining to clinical effectiveness and reimbursement issues related to
HDChx and ABMT or PSCT, since additional cancers appear to be likely candidates
for the treatment with requests for coverage by providers. Some of these include
ovarian cancer, small cell carcinoma of the lung, plasma cell myeloma, refractory
testicular carcinoma, and refractory, metastatic Ewing's sarcoma.
The need for continuous assessments is illustrated by my experiences during an
episode that occurred last year. A request for reimbursement for treatment of a
patient with testicular cancer with HDChx and ABMT was initially denied, and then
erroneously approved by Aetna in 1991. Since the treatment was certified, even
though in error, payment was made without question. The case, however, became the
topic of a prominent television news magazine program, providing a glaring example
of exploitation by a medically unsophisticated news medium of the "Canellos
standoff" on the topic of who should pay for the translation of laboratory science to
the bedside. Not only did my literature review at that time fail to provide sufficient
88TABLE 1
Patient Selection Criteria
StageIIandIIIBreast Cancer
A. Acceptable: patients who have received neo-adjuvant cytotoxic chemotherapy and have an adequate
hematologic status (white blood cell count > 4,000 mm3 and unmaintained platelet count of 100,000
mm3)
B. Age: not more than 60years ofage
C. Performance status: ECOG 2 or better; Karnofsky 60-70 or better
D. No history ofsecond malignancy or patient free ofdisease for five years; resected non-melanomatous
skin cancer or carcinoma in situ ofuterine cervix are not exclusion criteria
E. Negative HIV serology
F. No severe pulmonary disease; exclusion criteria: carbon monoxide diffusion capacity, less than 50
percent predicted; FEV, (forced expiratoryvolume in one second), less than 50 percent predicted;
PAO2, less than 60 mm Hg (torr)
G. MUGA: 50 percent ejection fraction or better in patients receiving cardiotoxic agents
H. Renal function adequate, as defined by: serum creatinine, not > 1.8 mg/dl, and creatinine clear-
ance, at least 40 ml/minute
I. Liver functions adequate, as defined by: serum bilirubin not > 2.0 mg/dl; SGOT not > two times
normal
J. Patients with stage II disease with ten or more positive axillary nodes are acceptable
K. Ifpatient has less than ten but six or more positive axillary nodes, she maybe considered an appro-
priate candidate ifpre-menopausal, estrogen receptor- and progesterone receptor-negative, and
meets criteria B through I
L. Inflammatory breast cancer or patients with locally advanced breast cancer, who, after loco-regional
therapy alone (surgery, with orwithout RT) show microscopic residual disease in the resected speci-
men are acceptable
M. Therapy to begin within eight weeks ofsurgery for the primary breast cancer
StageIVBreast Cancer
A. Acceptable: patients with metastatic disease who fail to achieve at least partial remission after three
cycles ofinitial standard chemotherapy and ifestrogen receptor- or progesterone receptor-positive,
also failed trial ofendocrine therapy, with adequate hematologic status (white blood cell
count > 4,000 mm3 and unmaintained platelet count of 100,000 mm3)
B. Also acceptable: patients who have relapsed less than a year after surgery for the primary breast can-
cer and adjuvant chemotherapy and have adequate hematologic status as defined above
C. Age: no more than 60years ofage
D. Untransplanted life expectancy ofat least sixweeks or more
E. Performance status: ECOG 3 or better; Karnofsky 40-50 or better
F. No history ofsecond malignancy unless free ofdisease for five years, except for resected non-mela-
nomatous skin cancer or carcinoma in situ ofthe uterine cervix
G. Negative HIV serology
H. No severe pulmonary disease; exclusion criteria: carbon monoxide diffusion capacity, less than 50
percent predicted: FEVI, less than 50 percent ofpredicted; PAO2, less than 65 mm Hg (torr)
I. MUGA: 50 percent ejection fraction orbetter in patients receiving cardiotoxic agents
J. Renal function adequate, as defined by: serum creatinine, not > 1.8 mg/dl, and creatinine clear-
ance, at least 40 ml/minute
K. Liver function adequate, as defined by: serum bilirubin not > 2 mg/dl, and SGOT not > two times
normal
L. Abnormal renal and liver funtion criteria not cause for exclusion when secondary to organ involve-
ment by metastatic disease
M. Sites ofdisease: acceptable are patients with less than three sites ofdisease. (Sites ofdisease are: [1]
soft tissue, [2] visceral, and [3] bone.) More than one metastasis in one site does not equate to
greater than one site. In order to include patients with advanced disease as defined by sites whose
functional impairment is less than might be expected, acceptable are patients with three sites ofdis-
ease who have a performance status ofECOG 2 or Karnofsky 60-70.
N. Estrogen receptor status: acceptable are estrogen receptor- and progesterone receptor-negative pa-
tients; or estrogen receptor- or progesterone receptor-positive patients who have hormonally refrac-
tory breast cancer
0. No intracranial metastases
P. Patients who receive standard induction chemotherapy should be responsive to the chemotherapy
administered prior to high-dose chemotherapy and autologous bone marrow or peripheral stem-cell
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TABLE 2
Evidence Tables for High-Dose Chemotherapywith ABMT for Breast Cancer
Stage II and Stage III Breast Cancerwith Ten or More Axillary Nodes:
Standard Regimens versus High-Dose Chemotherapy (HDChx) and
Autologous Bone Marrow Transplantation (ABMT)
Relapse-Free Survival (%)
Therapy No. ofPatients 1 Year 3 Years 5 Years
Standard-Dose Regimens 813 58-92 23-56 13-45
HDChx + ABMT 53 96 80 79.4
[39, 40]
Stage IV Breast Cancer:
Response to Repetitive Conventional-Dose Therapy (RCPT) versus Single High-Dose Treatment and
ABMT after Standard-Dose Induction Chemotherapy (HD + AT + IC)
Median (in months)
Complete
Remission Response Survival
Therapy No. ofPatients (%) Duration Duration
RCPT 3,734 373 (10) 7.6 13.9
HD + AT + IC 381 221 (58) 19 (estimated) >21
[42]
data to document the efficacy of HDChx and ABMT for testicular cancer, examina-
tion of the patient-specific clinical information showed that the treating physicians
had chosen this therapeutic intervention before all standard chemotherapeutic
regimens had been applied to the treatment ofthe patient's neoplasm. The sensitiv-
ityofembryonal cell carcinoma ofthe testis to manystandard chemotherapy options,
resulting in cure, is well known by medical oncologists. Application of an investiga-
tional, as yet unproven, treatment strategy before all standard chemotherapy regi-
mens had been reasonably applied does not appear to me to be responsible medical
practice. In spite ofbeing apprised ofthe lackofmedical logic in thisparticular case,
the news medium insisted upontelevising theiroriginal story, blamingthe third-party
payer for originally denying what was clearly investigational therapy, also implying
that the patient was harmed by a "delay" in treatment. The fact that standard
therapywaswithheldwhile awaiting approval forinvestigational therapywas ignored
in the television presentation. When the story was rerun in July 1991, there was still
no reference to the actual clinical facts which had previously been personally
presented to them.
New technologies continue to be developed and introduced rapidly into clinical
practice. For example, we reviewed the literature on extracorporeal photopheresis
for cutaneous T-cell lymphoma in 1989 and concluded that, since this treatment was
both safe and effective, it should be a covered benefit. Similarly, total electron beam
irradiation for severely generalized skin involvement in this disease (mycosis fun-
goides) appears to be preferable to topical nitrogen mustard application when given
incenterswith the special facilities able to satisfythe demanding technical aspects of
this therapy. It should be a covered benefit under these conditions. On the other
90CANCER THERAPY: REIMBURSEMENT
TABLE 3
Treatment Options for Metastatic Renal Cell Carcinoma: Median Survival
Median Survival
Treatment (months) Reference
Natural history 6.0 [43]
Conventional chemotherapy 7.0 [43]
IL-2/LAKa 6.2 [52]
IL-2 + beta interferon 7.2 [51]
IL-2 + mitogen-activated autologous lymphocytesa 10smaint. [52]
16 c maint. [52]
Interferons 8-10 [53]
Interferon beta serinea 7.5 [54]
Interferon gammaa 8.5 [55]
Interferon alpha + prednisone 11.0 [56]
Interferon alpha + gammaa 9.3 [57]
Interferon + chemotherapy 8-10 [58]
TIL ID [59]
TNF ID [60]
ALT 21.0 [47,48,49]
aMedian response duration to date ofpublication
ALT, autolymphocyte therapy
ID, insufficient data
TIL, tumor-infiltrating lymphocytes
TNF, tumor necrosis factor
hand, hyperthermic treatment of deep-seated, non-cutaneous cancers has yet to be
proven effective by controlled clinical trials and should notbe reimbursed.
Now the era ofimmunotherapy for cancer has arrived, with reimbursement issues
already commanding thoughtful consideration and research by third-party payers.
Some of these therapies will undoubtedly be initially promising, and requests for
insurance coverage forvery new or investigational treatments should be expected by
insurers, who will need to be ready with well-thought-out answers. As an example,
consider autolymphocyte therapy (ALT). Since this is a biological therapy, using the
patient's (or donor) cells, FDA approval will notbe needed.
Basically, ALT involves harvesting lymphocytes from a cancer patient, activating
these cells to become cytotoxic, and subsequently reinfusing them into the patient.
Toxicity has been minimal, in contrast to some other immunotherapies, such as
interleukin 2 plus lymphocyte-activated killer cells (IL-2/LAK) therapy. ALT is
currentlybeing investigated only for the treatment ofmetastatic renal cell carcinoma
(RCC), since this type is aneoplasm notoriously resistant to standard single-agent or
combinationcytotoxicchemotherapy. Median survivalofuntreated disease is approx-
imately six months, with less than a 10 percent two-year survival. With standard
agents, such as adriamycin plus cyclophosphamide, median survival is about seven
months [43]. Some therapeutic options formetastatic RCCinclude: notherapyother
than palliative measures, conventional chemotherapy, interferon alone or in combi-
nationwith chemotherapy, investigational treatmentwith interleukin 2plus lympho-
cyte-activated killer cells (IL-2/LAK), tumor-infiltrating lymphocytes (TIL), tumor
necrosis factor (TNF) alone or in combination with chemotherapy, and, finally, the
therapy under consideration: ALT [45-60]. Table 3 summarizes all options and
provides median survival times in months for each.
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Based upon a review of the literature and comparison with other therapies, ALT
of RCC appears to be promising and merits serious consideration for coverage by
third-party payers, although the firm data is derived from the most recent study,
which involved only 36 patients. Certainly this treatment, which involved six outpa-
tient treatments costing $2,000 each (total, $12,000) with no hospitalization, is much
more cost-effective (as well as safer and less toxic) than treatment with IL-2/LAK,
which usually involves a median two-week hospital stay, often in an intensive care
unit, and has a 3 to 5 percent treatment-related mortality. ALTtherapy also invokes
an additional, unique approach: the concomitant oral administration ofcimetidine,
which inactivates suppressor cells within the patient that might otherwise block the
resultant anti-tumor response. In summary, ALT, by combining specific in vitro
immunization with anti-suppressor cell treatment, results in a novel and improved
method of adoptive immunotherapy. Significantly, the quality oflife during therapy,
as indicated by an ECOG performance status of three or better until about two
months prior to death, was favorable and maybe translated into reduced health care
costs during the period ofremission.
Since the third-party payer assumes part or all of the reimbursement liability for
the health care costs of a patient with RCC-ethical considerations aside-it may
well be equally or more cost-effective to fund an early promising therapy such as
ALT, rather than to fund standard chemotherapy, which is not likely to provide
significant clinical benefit.
Finally, another new technology has emerged, requiring careful study by third-
party payers as they consider appropriate reimbursement criteria: colony-stimulating
factors [61-65]. In February 1991, granulocyte colony-stimulating factor (G-CSF)
was approved by the FDA for the labeled indication "to decrease the incidence of
infection, as manifested by febrile neutropenia, in patients with non-myeloid malig-
nancies receiving myelosuppressive anti-cancer drugs associated with significant
incidence of severe neutropenia and fever." Subsequently, on March 5, 1991,
granulocyte macrophage colony-stimulating factor (GM-CSF) received FDA ap-
proval. Labeling stated that it "is indicated for use in patients with non-Hodgkin's
lymphoma, Hodgkin's disease and acute lymphoblastic leukemia who are receiving
autologous bone marrowtransplants" (notperipheral stem-cell transplants).
Although the much broader labeling indications for G-CSF than for GM-CSF
have created controversy and confusion, many oncologists consider this instance to
be more a reimbursement challenge than a true clinical distinction. It isbelieved that
eventually G-CSF and GM-CSFwill be approvedboth for the amelioration offebrile
neutropenia associated with myelosuppressive chemotherapy and for the accelera-
tion ofrecovery afterbone marrow transplantation.
At present, there appears to be no question that co-administration ofG-CSFwith
myelosuppressive therapy will improve the likelihood that patients will be able to
tolerate chemotherapy cycles on schedule. This outcome is generally accepted by
medical oncologists as desirable, since dose reduction or cycle lengthening due to
leukopenia reduces dose intensity. Agroup ofpatientswith advanced bladder cancer
were treated at Memorial Sloan-Kettering Cancer Center in New York City with
G-CSF combined with the MVAC regimen (methotrexate, vinblastine, doxorubicin,
and cisplatin) every three weeks for four or five cycles. Historically, less than a third
of patients have been able to tolerate the MVAC regimen on schedule because of
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myelosuppression and low neutrophil counts. With the addition of G-CSF for seven
days after each cycle, 100 percent of patients were able to go on the next cycle [64].
Whether it will be possible to escalate doses of chemotherapeutic agents in
conjunction with G-CSF and achieve clinically effective results is the subject of
ongoing trials. Although the use of colony-stimulating factors may shorten the
duration of neutropenia to a period of six to eight days, its depth may well be
unchanged. It is recognized that the more chemotherapy given, the more the supply
of cells that can respond to growth factors is depleted. Patients still are subject to
prolonged nadirs when cell counts are low. The maximum tolerated doses (MTDs)
that have been established for standard chemotherapy agents over the last 30 years
are based on the numbers of stem cells left in the bone marrow after treatment.
Growth factors have not changed those numbers: it is not possible to escalate beyond
the MTDbecause the population ofcells that can respond to growth factors has been
eliminated [64].
Turning to clinical studies of GM-CSF [61,62], the treatment of patients with this
factor following ABMT results in fewer days of infection and improved white blood
cell counts compared to untreated patients. As a result, these patients needed fewer
antibiotics and, in some cases, shorter hospitalizations. Side effects associated with
moderate doses ofGM-CSF have generallybeen mild and easily managed. In clinical
trials, diarrhea, skin rash, weakness, and malaise were found in only 5 percent more
subjects treated with GM-CSF than in the placebo group [65]. More serious toxicity
associated with GM-CSF has been reported and includes myalgias, bone pain,
low-grade temperature, flushing episodes, pericardial effusions, and serositis-type
episodes. These, however, appear to be dose-related: subsequent studies using lower
doses of GM-CSF have been shown to be equally effective and not associated with
significant toxicity [64].
An important issue that still remains unresolved is whether the dose escalation of
cancer chemotherapeutic agents facilitated by the use of colony-stimulating factors
will result in the appearance of non-hematologic toxicities such as cardiac, pulmo-
nary, central nervous system, and gastrointestinal types.
Also, neither G-CSF nor GM-CSF exert any beneficial effect on platelets and may
actually have some adverse effect on platelet counts. Whether the mild thrombocyto-
penia is clinically relevant remains to be studied. This lack of effect on thrombocytes
has stimulated research into the newer cytokines, such as IL-3, stem-cell factor, and
the "pixie molecule" (combination of IL-3 plus GM-CSF), all of which may have
specific effects on platelets.
Cost efficacy represents another area of uncertainty. Higher-than-usual dose
chemotherapy followed by G-CSF will result in a shorter period of neutropenia, but
it has been observed that prophylactic antibiotics may be just as effective and less
costly. In the setting ofbone marrow transplantation, however, there appears to be a
consensus that appropriate use of GM-CSF should result in reduced overall costs.
Dr. James 0. Armitage, ofthe University ofNebraska School ofMedicine in Omaha,
Nebraska, has been quoted as saying, "Investing $3,000 in a drug that prevents a
$20,000 hospital stay seems quite cost-effective [64]."
Other studies support the use of CSFs [65]. In one study of GM-CSF at the Fred
Hutchinson Cancer Research Center in Seattle, the average hospital stay forpatients
with successful marrow transplants was reduced from 43 days to 28 days, and average
treatment cost fell from $112,000 to $79,000.
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In amulti-center, double-blinded, randomized, placebo-controlled trialofpatients
treated with cancer chemotherapy, those receiving G-CSF required50percent fewer
hospitalizations for febrile neutropenia than those who did not receive the agent.
The amount saved per cycle of chemotherapy ranged from $753 to $5,117 and
appeared to be related to the patient's health insurance (Medicare versus private)
and among different hospitals. Medicare program savings ranged from $1,007 to
$1,638.
How, then, should new technologies for cancer therapy be reimbursed? Off-label
use, new technologies endorsed by "gold-standard" organizations (like DATTA)
applied in cancers for which other treatments are available and more cost-effective,
new technologies that appear promising and potentially cost-effective but not yet
reviewed by an unbiased panel of experts all may require simple or enormously
complex technology assessments in order to arrive at a logical, defensible, and, it is
hoped, cost-effective reimbursement policybythird-party payers.
The decision process would involve literature review and expert panel consulta-
tion. Clearly, if a treatment is already established as effective and broadly accepted,
there is no reimbursement issue and coverage should be certified. Unfortunately,
investigational therapy is often not clearly defined in standard contract language.
What constitutes investigational therapy may become a legal rather than a clinical
issue. These considerations notwithstanding, if a new technology is identified as
investigational, literature review and consultation with an expert panel are necessary
to arrive at a coverage decision.
New technologies that are investigational but deemed promising by this review
process should be eligible for reimbursement; this payment should include all
reasonable costs associated with treatment ofthe cancer patient. On the other hand,
investigational therapy identified as not promising after literature review and impar-
tial panel assessment shouldnotbe covered. Ideally, this decisionprocess should also
incorporate a method to review both old as well as new technologies, in order to
identify ineffective or obsolete treatments that should no longer be eligible for
coverage.
This route appears to be a rational approach to the issue of reimbursement of
cancer therapy by third-party payers. The examples provided should have made the
following problems and goals clear:
This effort can be a complex, ongoing endeavor.
Asignificant investment oftime, personnel, and funds are required.
The reimbursement decision must be considered fair by the practicing commu-
nityofoncologists.
The reimbursement decision should be cost-effective.
Theprocess should result insignificant reduction intherisingrateofhealthcare
costs.
The process should include a method of discontinuing reimbursement of
ineffective or obsolete technology.
The process should encourage development ofpromising new treatments.
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